Freenome, Inc. Stock: price and insider trades · United States
Freenome, Inc.: what insiders have been doing
Freenome, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). In the past year (17 November 2025 to 17 November 2026), 15 filings came from 9 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Compared with its exchange (3,169 companies, median 24 filings), a count of 15 filings is below the norm. For the fiscal year to 31 December 2025, the annual 10-K puts net income at 837,468 USD.
Over the last twelve months, not one insider purchase of Freenome, Inc. stock was filed. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Analyst consensus: bullish or bearish?
Analysts rate Freenome, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$18.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 71,920 shares@ US$15.250.063% mcap100.0% of flowCommon StockSEC:0001140361-26-035816:0
- 30,000 sharesCommon StockSEC:0001449008-26-000004:0
- 30,000 sharesCommon StockSEC:0001602787-26-000004:0
- 2,066,250 sharesCommon StockSEC:0002017632-26-000004:0
- 6,561,711 sharesCommon StockSEC:0001231919-26-000783:0
- 970,950 sharesCommon StockSEC:0001231919-26-000783:1
- 553,703 sharesCommon StockSEC:0001231919-26-000783:2
- 908,103 sharesCommon StockSEC:0001231919-26-000783:3
- 367,427 sharesCommon StockSEC:0001231919-26-000783:4
- 2,066,250 sharesCommon StockSEC:0001727440-26-000003:0
- 30,000 sharesCommon StockSEC:0001749623-26-000003:0
- 2,066,250 sharesCommon StockSEC:0001746738-26-000003:0
- 5,500,000 shares@ US$10.003.18% mcap100.0% of flowCommon StockSEC:0001193125-26-312798:0
- 4,918,411 shares@ US$10.002.84% mcap93.6% of flowCommon StockSEC:0001231919-26-000783:5
- 336,965 shares@ US$10.000.19% mcap6.4% of flowCommon StockSEC:0001231919-26-000783:6
- 286,250 shares@ US$10.00100.0% of flowClass A ordinary sharesSEC:0001140361-24-030027:0
- 286,250 shares@ US$10.00100.0% of flowClass A ordinary sharesSEC:0001140361-24-030023:0
- 286,250 shares@ US$10.00100.0% of flowClass A ordinary sharesSEC:0001140361-24-030029:0
18 of 18 declarations
About Freenome, Inc.
Freenome, Inc. is a biotechnology company that uses artificial intelligence to detect cancer at an early stage. It focuses on developing blood-based screening tests to improve patient outcomes.
Written on 23 July 2026 from the filings and market data available that day. Live figures are in the blocks above.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendationsThe weekly insider digest, free
One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.
